Cytokinetics oral heart failure agent begins Phase I
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After releasing top-line results of its Phase I intravenous CK-1827452 candidate to treat acute and chronic heart failure, Cytokinetics announced it will begin Phase I trials of an oral formulation of the compound. The company hopes to study the intravenous formulation in acutely decompensated heart failure patients in a hospital setting and transition them to an oral dose in an outpatient setting. Cytokinetics is already considering a sales force of 100-200 full-time employees for the drug (1Pharmaceutical Approvals Monthly August 2006, p. 6)...
|
After releasing top-line results of its Phase I intravenous CK-1827452 candidate to treat acute and chronic heart failure, Cytokinetics announced it will begin Phase I trials of an oral formulation of the compound. The company hopes to study the intravenous formulation in acutely decompensated heart failure patients in a hospital setting and transition them to an oral dose in an outpatient setting. Cytokinetics is already considering a sales force of 100-200 full-time employees for the drug (1 Pharmaceutical Approvals Monthly August 2006, p. 6).... |